Text Size
69 studies found for:    gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown † Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery
Condition: Breast Cancer
Interventions: Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Genetic: microarray analysis;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
2 Recruiting Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: paclitaxel;   Drug: sorafenib tosylate;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
3 Recruiting MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: Akt inhibitor MK2206;   Procedure: therapeutic conventional surgery;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Procedure: neoadjuvant therapy
4 Recruiting Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Condition: Breast Cancer
Interventions: Drug: nab-paclitaxel;   Drug: trastuzumab;   Drug: Doxorubicin;   Drug: cyclophosphamide
5 Recruiting Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: tivantinib;   Other: laboratory biomarker analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: immunohistochemistry staining method
6 Recruiting Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Condition: Breast Cancer
Interventions: Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: adjuvant therapy;   Procedure: quality-of-life assessment;   Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation
7 Recruiting A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel + LCL161;   Drug: paclitaxel
8 Recruiting DIG-HIF1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Digoxin
9 Not yet recruiting Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism
Condition: Breast Cancer
Intervention: Drug: Capecitabine
10 Recruiting PET Study of Breast Cancer Patients Using [68Ga]ABY-025
Condition: Breast Cancer
Intervention: Drug: [68Ga]ABY-025
11 Recruiting Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Abraxane;   Drug: Bevacizumab;   Drug: Carboplatin
12 Recruiting Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer
Conditions: Breast Cancer;   Breast Cancer Stage II-III
Intervention: Drug: Docetaxel- Carboplatin
13 Unknown † PET-Guided Chemotherapy and Hormone Therapy in Treating Women With Previously Untreated Invasive Breast Cancer
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Biological: trastuzumab;   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: epirubicin hydrochloride;   Drug: vinorelbine tartrate;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Procedure: neoadjuvant therapy;   Procedure: positron emission tomography;   Procedure: therapeutic conventional surgery
14 Unknown † Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Simvastatin
15 Recruiting Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer
Condition: Breast Cancer
Intervention: Drug: BKM120 + lapatinib
16 Recruiting Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Eribulin
17 Not yet recruiting The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: gefitinib
18 Recruiting A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Epirubicin+Cyclophosphamide;   Drug: liposomal-doxorubicin+Cyclophosphamide
19 Unknown † Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor
Condition: Breast Cancer
Intervention: Drug: Doxorubicin, Cyclophosphamide
20 Recruiting ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Conditions: Neoplasms, Breast;   Breast Cancer
Interventions: Drug: Lapatinib;   Biological: Trastuzumab
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years